FSD Pharma Inc (HUGE)
CNSX 
NASDAQ (CM) Primary CNSX Summary
HUGE Chart
Quantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price
TORONTO, ON / ACCESSWIRE / November 25, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) (the "Company") formerly named FSD Pharma Inc. (Nasdaq:HUGE)(CSE:HUGE) is pleased to follow up on recent events concerning the complaint filed by the Company in the United States courts, that alleges that CIBC World Markets, RBC Dominion Securities and others (the "Defendants") engaged in market manipulation in the share price of the Company.
FSD Pharma Inc (HUGE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has FSD Pharma Inc ever had a stock split?
FSD Pharma Inc Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Zeeshan Saeed CEO | CNSX Exchange | CA35954B4047 ISIN |
| CA Country | 17 Employees | - Last Dividend | 15 Aug 2024 Last Split | - IPO Date |
Overview
Quantum BioPharma Ltd. is an innovative biopharmaceutical company dedicated to the discovery and development of novel therapeutics for neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders. Focused on addressing some of the most challenging medical conditions, the company's approach combines cutting-edge research with strategic investments to propel its portfolio of drug candidates through different stages of development. With its headquarters in Toronto, Canada, Quantum BioPharma operates in two primary segments: Biopharmaceutical, which encompasses its research and development activities, and Strategic Investments, through which it manages a portfolio including loans secured by residential property. Originally known as FSD Pharma Inc., the company renamed to Quantum BioPharma Ltd. in August 2024, marking a new phase in its mission to revolutionize patient care in its target therapeutic areas.
Products and Services
Quantum BioPharma Ltd. is developing a diverse portfolio of products and services designed to meet urgent healthcare needs:
- Lucid-MS: This lead compound represents a significant advance in the treatment of Multiple Sclerosis (MS). It is a patented new chemical entity currently in Phase 2 clinical trials. Lucid-MS has shown promise in preventing and reversing myelin degradation, which is a fundamental cause of MS, in preclinical models. By targeting the underlying mechanism of the disease, Lucid-MS has the potential to offer a groundbreaking treatment option for patients suffering from this debilitating condition.
- Treatment for Alcohol Misuse Disorders: Addressing the critical need for effective interventions in alcohol misuse, Quantum BioPharma is developing a novel treatment aimed at hospitals and medical practices. This initiative reflects the company's commitment to expanding its therapeutic reach into areas of high unmet medical need, providing new hope for individuals struggling with alcohol dependency.
- Strategic Investments: Beyond its biopharmaceutical endeavors, Quantum BioPharma maintains a strategic investment portfolio. This includes loans secured by residential property, diversifying the company’s assets and providing a financial foundation to support its core mission in drug development. These investments represent a prudent approach to sustaining the company’s growth and ensuring the continued advancement of its therapeutic pipeline.
